About
Eleusis develops new psychedelic-based therapeutics by focusing on serotonin 2A receptor agonists and aims to mitigate and manage their psychoactive effects for mental health treatment.
Explore Eleusis's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.